Clinical trial
Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or…
NCT00043953 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00043953 |
|---|---|
| Title | Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects |
| Official title | A Phase II Study of Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lopinavir/ritonavir, Saquinavir mesylate, Lamivudine/zidovudine |
| Enrollment | 30 |
| Start date | Aug 1, 2002 |
| First posted | Aug 19, 2002 |
| Last update posted | Sep 27, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: